AmnioAMP Application Protocol: Step-by-Step Guide for Wound Care Teams (2026 Update)
AmnioAMP is a dehydrated human amniotic membrane (amnion/chorion) allograft applied as an advanced wound covering under HCPCS Q4250; this page is the step-by-step application protocol wound care teams follow, from patient selection through coding documentation.
A repeatable application protocol is one of the highest-leverage controls a wound center has over biologic outcomes. For dehydrated human amniotic membrane products such as AmnioAMP-MP from NextGen Biologics USA, graft success depends less on a single clinician's judgment than on a documented sequence every team member follows: wound-bed preparation, correct handling, appropriate dressing, scheduled reassessment — and coding documentation captured at the point of care. Sen framed the contemporary wound-care landscape as a "patchwork" of inconsistent practices and argued that standardization is the missing link between available therapies and reliable results (PMID 38940743). This guide turns that principle into an office-ready AmnioAMP-MP protocol, with the coding and reimbursement detail teams most often ask about.
---
Why Protocol Standardization Matters
Multidisciplinary wound care teams remain the dominant delivery model for complex wounds, and team-based care is associated with reduced major amputations in diabetic foot ulcer populations (PMID 31676181). But team structure alone does not produce consistent outcomes — protocols do. Contemporary DFU guidance continues to emphasize structured, guideline-concordant care pathways (PMID 28116957). For AmnioAMP-MP specifically, a written protocol protects against the failure modes we see most often in protocol audits:
- Inconsistent wound-bed preparation before graft placement - Variable rehydration times and handling technique - Dressing choices that desiccate or macerate the graft - Missing documentation of medical necessity, lot numbers, and square centimeters applied — the three data points payers audit first - Unclear reassessment intervals and reapplication triggers
A protocol also accelerates onboarding, supports accreditation review, and creates a baseline for quality-improvement cycles.
---
What AmnioAMP-MP Is — and How It Differs from Standard Grafts
AmnioAMP-MP is a single-layer dehydrated human amniotic membrane allograft (HCPCS Q4250) supplied at room temperature. It is not a cryopreserved product, not a cellular construct, and not a xenograft — and those distinctions drive both handling and coding decisions. Dehydrated human amnion/chorion membrane (dHACM) has category-level randomized evidence in diabetic foot ulcers: a multicenter RCT of 80 patients showed improved healing likelihood and rate versus standard care (PMID 30019528), and a confirmatory 110-patient multicenter RCT reproduced the benefit (PMID 30136445). A 2022 systematic review and meta-analysis concluded amniotic membrane products improve DFU outcomes versus standard care (PMID 36104736), and a 2025 Japanese case series demonstrated effective closure in routine practice (PMID 41251011). A podiatric medicine review likewise summarizes dHACM as an established DFU adjunct (PMID 33872365).
| Selection factor | AmnioAMP-MP (dHACM) | Standard skin substitute / cellular construct | Conventional dressings | |---|---|---|---| | Format | Dehydrated single-layer membrane, room-temperature | Often frozen, refrigerated, or bilayer cellular construct | N/A — no graft applied | | Handling burden | 2–3 min saline rehydration; atraumatic forceps | Cold-chain or complex thawing; some require suturing | Minimal | | Evidence in DFU | RCT + confirmatory RCT + meta-analysis (PMID 30019528; PMID 30136445; PMID 36104736) | Product-specific; heterogeneous | Standard of care comparator in the trials above | | HCPCS | Q4250, per sq cm | Product-specific (e.g., Q4100 series, C-codes) | A6250-series dressings | | Best fit | Small-to-medium DFU/VLU after optimized SOC stalls | Deeper or larger defects per product labeling | First-line and maintenance therapy |
A trial-based health economics analysis found dHACM cost-effective versus standard care alone in Wagner 1 DFUs (PMID 32729342), and placental membrane has shown both improved healing efficacy and lower cost versus a tissue-engineered human skin product in DFU (PMID 31592387). A 2024 cost-effectiveness analysis extended the case to venous leg ulcers (PMID 38457290). Cost-effectiveness, however, depends on appropriate patient selection — applying biologics indiscriminately erodes the economic case, a point Carter pressed in a 2025 analysis of justifiable price limits per square centimeter for cellular/tissue-based products (PMID 38832861).
For the dual-layer alternative in the NextGen portfolio, see AmnioAMP vs Rampart: Clinical Comparison 2026; for the product-level evidence and reimbursement comparison against the category's most-published DHACM allograft, see AmnioAMP vs EpiFix: A Clinician's Comparison; for processing-format context, see Dehydrated vs Cryopreserved Amniotic Membrane: A Clinician's Guide.
---
Wound-Type Suitability for AmnioAMP-MP
Per manufacturer labeling, AmnioAMP-MP is intended for partial- and full-thickness acute and chronic wounds as a wound covering. Clinicians most often reach for it in:
- Diabetic foot ulcers — after optimized standard of care (offloading, debridement, infection control, moisture management) has stalled (PMID 30019528; PMID 30136445; PMID 36104736) - Venous leg ulcers — when compression alone has not produced adequate closure progress (PMID 38457290) - Small-to-medium surgical or traumatic wounds where conformability to an irregular bed is advantageous - Ambulatory or satellite clinics lacking freezer capacity for cryopreserved products
Caution: Do not apply to actively infected wounds without source control, untreated osteomyelitis, or wounds with inadequate perfusion; do not use as a first-line dressing before an optimized standard-of-care trial.---
Pre-Application Checklist
1. Indication and IFU match — wound etiology consistent with product labeling. 2. Informed consent — patient understands biologic allograft use and follow-up requirements. 3. Infection control — no spreading cellulitis, untreated deep-space infection, or gross purulence (PMID 28116957). 4. Perfusion — adequate vascular status documented for lower-extremity wounds. 5. Offloading plan — in place for plantar DFUs and pressure injuries. 6. Product integrity — package unopened, within expiration, correct size available. 7. Documentation tools — wound photography, planimetry measurements, EHR flowsheet ready.
---
Step-by-Step AmnioAMP-MP Application Protocol
Step 1: Wound-bed preparation. Debride sharply to viable tissue; remove slough and biofilm; control hemostasis. Cleanse with sterile saline or a non-cytotoxic surfactant cleanser. Avoid povidone-iodine, hydrogen peroxide, or sodium hypochlorite immediately before graft placement — residual cytotoxicity impairs granulation. The bed should be moist, not saturated. Step 2: Sizing. Measure length, width, depth. Use digital planimetry or the ellipse formula (length × width × π/4). Select a sheet covering the wound with 1–2 mm overlap onto periwound skin. Record the calculated square centimeters — this is your Q4250 billing unit. Avoid overlapping multiple sheets; place edge-to-edge if needed. Step 3: Rehydration. Open the outer pouch aseptically; transfer the inner sterile pouch to the field. Place the dehydrated sheet in room-temperature sterile saline for 2–3 minutes. Do not over-soak; prolonged immersion may leach matrix-bound factors. Handle with atraumatic forceps once pliable. Step 4: Orientation and placement. Place the rehydrated sheet per the manufacturer's Instructions for Use. Smooth from the center outward to eliminate air pockets. Do not suture or staple; fixation comes from the secondary dressing. Step 5: Secondary dressing selection.| Exudate level | Suggested secondary dressing | Rationale | |---|---|---| | Dry to minimal | Thin hydrocolloid or foam | Maintains moisture without maceration | | Moderate | Silicone-bordered foam | Absorbs exudate, atraumatic removal | | Heavy | Calcium alginate or hydrofiber under foam | Manages fluid load while protecting graft |
Apply a non-adherent contact layer directly over the graft, then the absorbent secondary. Secure without tension or shear.
Step 6: Offloading and protection. Total contact cast, rendered-irremovable removable cast walker, or surgical shoe with relief insert for plantar wounds; pressure-redistribution surfaces for pressure injuries. Step 7: Documentation. Record indication, wound measurements, prior SOC response, product lot number, size applied, square centimeters billed, application date, dressing type, offloading method, and follow-up interval. Link the note to the medical-necessity rationale payers require.---
Coding and Reimbursement Notes (Q4250 + CPT 15271–15278)
| Element | Detail | Verification step | |---|---|---| | Product code | HCPCS Q4250, dehydrated amniotic membrane, per square centimeter | Confirm descriptor in the current CMS HCPCS Level II file; Q-codes are product-specific — do not substitute | | Application code | CPT 15271–15278 (skin substitute application, by site and size) | Match the body-site range and total sq cm to the correct code in the 15271–15278 series | | Medical necessity | Document failed optimized SOC, wound measurements, and expected closure trajectory | Most MAC LCDs require documented SOC failure before biologic coverage | | Units | Bill Q4250 in the square centimeters actually applied, recorded at Step 2 | Audit exposure: payers reconcile billed units against planimetry in the note | | Cost framing | dHACM cost-effective vs SOC in Wagner 1 DFU (PMID 32729342); per-sq-cm price limits are a live policy debate (PMID 38832861) | Track cost per closed wound, not cost per application |
Coverage policies vary by MAC and evolve; verify with your local Medicare Administrative Contractor before claim submission. Nothing in this protocol substitutes for current CMS and payer guidance.
---
Follow-Up and Reapplication Schedule
| Visit | Timing | Assessment focus | Reapplication trigger | |---|---|---|---| | First | Day 5–7 | Graft uptake, infection signs, exudate, periwound skin | < 50% graft take or exposed wound bed | | Second | Day 12–14 | Wound-area reduction, epithelialization, granulation | Worsening or stalled trajectory | | Formal reassessment | Week 4 | ≥ 40–50% area reduction expected if responding | Reassess perfusion, infection, offloading, nutrition |
If response is inadequate at 4 weeks, revisit the fundamentals — perfusion, infection control, offloading, glycemic control, nutrition — before adding applications.
---
Frequently Asked Questions
Q: What is AmnioAMP-MP and who manufactures it?AmnioAMP-MP is a single-layer dehydrated human amniotic membrane allograft manufactured by NextGen Biologics USA. It is regulated as a Section 361 HCT/P when intended for homologous use and billed under HCPCS Q4250 per square centimeter applied.
Q: How does AmnioAMP-MP compare with standard grafts and cellular constructs?It is dehydrated and room-temperature rather than cryopreserved, requires no suturing, and carries RCT-level DFU evidence (PMID 30019528; PMID 30136445) plus meta-analytic support (PMID 36104736). Comparative cost data versus a tissue-engineered skin product favor placental membrane (PMID 31592387).
Q: What HCPCS and CPT codes apply to AmnioAMP-MP?Q4250 for the product (per sq cm) paired with CPT 15271–15278 for application. Verify the current descriptors and your MAC's coverage criteria before billing.
Q: Does AmnioAMP-MP require refrigeration?No. It is a dehydrated, room-temperature-stable product requiring a 2–3 minute sterile saline rehydration before application.
Q: Can it be applied to infected wounds?No. Control active infection, including osteomyelitis and spreading cellulitis, before application (PMID 28116957).
Q: When should the wound be reassessed?First reassessment at 5–7 days for graft uptake and dressing adequacy; formal response assessment at 4 weeks.
Q: What does the evidence say for diabetic foot ulcers specifically?An 80-patient RCT showed improved healing likelihood and rate (PMID 30019528); a 110-patient confirmatory RCT reproduced the result (PMID 30136445); a 2022 meta-analysis supports the category (PMID 36104736); and a 2025 case series shows effectiveness in routine practice (PMID 41251011).
Q: Is dHACM cost-effective?A trial-based analysis found dHACM cost-effective versus SOC in Wagner 1 DFUs (PMID 32729342), with a 2024 extension to venous leg ulcers (PMID 38457290) — provided selection criteria are enforced (PMID 38832861).
---
About NextGen Biologics USA
NextGen Biologics USA is a wound-care biologics company focused on evidence-based amniotic membrane products for clinical decision-making. The portfolio includes AmnioAMP-MP (single-layer dehydrated amniotic membrane, HCPCS Q4250) and Rampart DL Matrix (dual-layer dehydrated amniotic membrane, HCPCS Q4347). All products are minimally manipulated, regulated under Section 361 of the Public Health Service Act for homologous use, and supplied at room temperature without cold-chain requirements. For product information, clinical evidence summaries, and application resources, visit the NextGen Biologics USA product page.
---
Related AmnioAMP Resources
- AmnioAMP reapplication schedule & storage FAQ — cadence rules, visit timing, and storage/rehydration answers for scheduling and inventory staff. - In-office AmnioAMP-MP application technique — single-visit technique and dressing detail. - AmnioAMP vs EpiFix comparison — evidence, coding, and selection framework versus the category's most-published DHACM allograft. - AmnioAMP vs Rampart DL Matrix comparison — dual-layer versus single-layer selection. - AmnioAMP clinical outcomes: DFU case series review — peer-reviewed healing outcomes. - What is AmnioAMP? product overview — mechanism, sourcing, and HCPCS Q4250 coding.
--- - Diabetic Foot Ulcer Treatment Guidelines 2026: Where
References
1. Sen CK. Standardized Wound Care: Patchwork Practices? Adv Wound Care. 2024. PMID: 38940743. 2. Musuuza J, et al. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. J Vasc Surg. 2020. PMID: 31676181. 3. Lim JZ, et al. Prevention and treatment of diabetic foot ulcers. J R Soc Med. 2017. PMID: 28116957. 4. DiDomenico LA, et al. Use of an aseptically processed, dehydrated human amnion and chorion membrane improves likelihood and rate of healing in chronic diabetic foot ulcers. Int Wound J. 2018. PMID: 30019528. 5. Tettelbach W, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers. Int Wound J. 2019. PMID: 30136445. 6. Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers: do they help? A systematic review and meta-analysis. J Foot Ankle Res. 2022. PMID: 36104736. 7. Terabe Y, et al. Effectivity of the Dehydrated Human Amnion/Chorion Membrane Allograft for Diabetic Foot Ulcers in Japan: A Case Series. Int Wound J. 2025. PMID: 41251011. 8. Au AS, et al. Efficacy of Dehydrated Human Amnion Chorion Membrane in the Treatment of Diabetic Foot Ulcers: A Review. J Am Podiatr Med Assoc. 2021. PMID: 33872365. 9. Carter MJ. Dehydrated human amnion and chorion allograft versus standard of care alone in treatment of Wagner 1 diabetic foot ulcers: a trial-based health economics study. J Med Econ. 2020. PMID: 32729342. 10. Glat P, et al. Placental Membrane Provides Improved Healing Efficacy and Lower Cost Versus a Tissue-Engineered Human Skin in the Treatment of Diabetic Foot Ulcerations. Plast Reconstr Surg Glob Open. 2019. PMID: 31592387. 11. Tettelbach WH, et al. Dehydrated human amnion/chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024. PMID: 38457290. 12. Carter MJ, et al. Counting the Cost of Cellular and/or Tissue-Based Products in Diabetic Foot Ulcers: Is There a Justifiable Price Limit per Square Centimeter? Adv Wound Care. 2025. PMID: 38832861.
---
Disclaimer: This protocol is an educational resource for clinicians and healthcare decision makers, not a substitute for the manufacturer's Instructions for Use, institutional policy, or clinical judgment. Reimbursement and coverage policies change frequently. Verify all coding, coverage, and product specifications with the current CMS HCPCS Level II file, the manufacturer's Instructions for Use, and your local Medicare Administrative Contractor before application or claim submission.